Clene (CLNNW) Treasury Stock : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Clene Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Clene's treasury stock for the quarter that ended in Mar. 2024 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Clene Treasury Stock Historical Data

The historical data trend for Clene's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene Treasury Stock Chart

Clene Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Treasury Stock

Clene Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Treasury Stock	Get a 7-Day Free Trial													-	-	-	-	-

Clene Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Clene (CLNNW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNNW) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

CLNN:USA 84C:Germany

Address

6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121

Website

https://www.clene.com

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).